Published on 18 Mar 2024 on Zacks via Yahoo Finance
Laboratory Corporation of America Holdings, Inc. or Labcorp LH recently highlighted results from two studies at the 2024 SGO Annual Meeting on Women's Cancer. The trials demonstrate how biomarker testing can help close testing gaps and guide tailored therapy for patients with epithelial ovarian cancer (EOC).
With the rapid identification of cancer biomarkers and the development of new targeted medicines, thorough testing procedures are becoming increasingly important as treatment guidelines advance. Labcorp researchers conducted two studies to provide additional evidence of the utility of complete genetic profiling in driving guideline-compliant testing, which increases patient access to targeted medicines for better results.
Study Details